During the forecast period 2023 to 2033, the Severe hypertriglyceridemia (SHTG) treatment market is expected to grow at a value of 14.3% CAGR, according to Future Market Insights. By the year 2033, the global market for Severe hypertriglyceridemia (SHTG) treatment is expected to rise up to a market valuation of US$ 2675.37 Million. The global SHTG treatment market has been witnessing substantial growth in recent years, and this trend is expected to continue in the coming years.
One of the major factors driving the growth of the SHTG treatment market is the increasing prevalence of hypertriglyceridemia worldwide. According to the American Heart Association, hypertriglyceridemia affects around one-third of the adult population in the United States alone. This has led to an increased demand for effective treatment options for SHTG.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-16823
Another factor driving the growth of the SHTG treatment market is the increasing adoption of personalized medicine. Personalized medicine involves the use of individual patient data to develop customized treatment plans based on the patient’s unique genetic makeup and medical history. This approach has been gaining popularity in recent years, and many companies are now focusing on developing personalized treatment options for SHTG.
Key Takeaways from the Global Severe Hypertriglyceridemia (SHTG) Treatment Industry Study
- The global Severe hypertriglyceridemia (SHTG) treatment market is expected to grow with a 14.3% CAGR during 2023 to 2033.
- Hospital pharmacies are expected to hold 40% of the market share in 2023 for Severe hypertriglyceridemia (SHTG) treatment market.
- North America is expected to possess 45% market share for Severe hypertriglyceridemia (SHTG) treatment market in 2023.
- Europe severe hypertriglyceridemia (SHTG) treatment market size is expected to possess 39% market share in 2023.
“As more innovative therapies and drugs are developed, the market for SHTG treatment is likely to become even more competitive, with companies vying for a larger share of the market.” states an FMI analyst
Ask Us Your Questions About This Report
https://www.futuremarketinsights.com/ask-question/rep-gb-16823
Global Severe Hypertriglyceridemia (SHTG) Treatment Industry Competitive Landscape
Key players in the severe hypertriglyceridemia (SHTG) treatment market are Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., NorthSea Therapeutics B.V., Amryt Pharma, Afimmune Pharmaceutical, Zucara Therapeutics, Novo Nordisk, Adocia and Pfizer Inc.
- Arrowhead Pharmaceuticals Inc lead drug candidate for SHTG is ARO-APOC3, an RNA interference (RNAi) therapeutic agent designed to target and silence the production of apolipoprotein C-III (APOC3), a protein that plays a key role in regulating triglyceride levels in the blood. In preclinical studies, ARO-APOC3 has been shown to significantly reduce triglyceride levels in animal models of SHTG.
- NorthSea Therapeutics B.V lead drug candidate is called MBOAT7, which is an enzyme that plays a key role in the production of phosphatidylinositol-5-phosphate (PI5P), a lipid that is involved in regulating lipid metabolism. In preclinical studies, MBOAT7 has been shown to reduce triglyceride levels in animal models of SHTG.
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Severe hypertriglyceridemia (SHTG) treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights based on Drug Class (Olezarsen, Pegozafermin, Epeleuton, Lomitapide) Drug Delivery Method (Oral Route, Injectable Route) Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa)
Grab Your Report on Discount Before It’s Gone!
https://www.futuremarketinsights.com/request-discount/rep-gb-16823
Key Segments Profiled in the Global Severe Hypertriglyceridemia (SHTG) Treatment Industry Survey
Drug Class:
- Olezarsen
- Pegozafermin
- Epeleuton
- Lomitapide
Drug Delivery Method:
- Oral Route
- Injectable Route
Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
